Eltoprazine (; developmental code name DU-28,853) is a non-selective serotonin receptor modulator of the phenylpiperazine family which was under development for the treatment of aggression, attention deficit hyperactivity disorder (ADHD), cognition disorders, drug-induced dyskinesia, and psychotic disorders but was never marketed. It has been described as a "serenic" or antiaggressive agent. The drug is taken orally.
via PubMed
Eltoprazine (; developmental code name DU-28,853) is a non-selective serotonin receptor modulator of the phenylpiperazine family which was under development for the treatment of aggression, attention deficit hyperactivity disorder (ADHD), cognition disorders, drug-induced dyskinesia, and psychotic disorders but was never marketed. It has been described as a "serenic" or antiaggressive agent. The drug is taken orally.
It acts as an agonist of the serotonin 5-HT1A and 5-HT1B receptors and as an antagonist of the serotonin 5-HT2C receptor (Ki = 40nM, 52nM, and 81nM, respectively). The drug also shows weaker affinity for certain other serotonin receptors and targets. The pharmacokinetics of eltoprazine have been studied. Eltoprazine is closely related to fluprazine and batoprazine, which are similarly acting agents, and is also a known chemical precursor to S-15535 and lecozotan.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).